Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Kleeff, 2016, Pancreatic cancer, Nat Rev Dis Primers, 2, 16022, 10.1038/nrdp.2016.22

Cunningham, 2009, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer, J Clin Oncol, 27, 5513, 10.1200/JCO.2009.24.2446

Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369

Sultana, 2007, Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer, J Clin Oncol, 25, 2607, 10.1200/JCO.2006.09.2551

Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923

Neoptolemos, 2001, ESPAC-1: A European, randomized controlled study of adjuvant chemoradiation and chemotherapy in resectable pancreatic cancer, Lancet, 358, 1576, 10.1016/S0140-6736(01)06651-X

Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 350, 1200, 10.1056/NEJMoa032295

Oettle, 2013, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, 310, 1473, 10.1001/jama.2013.279201

Neoptolemos, 2009, Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials, Br J Cancer, 100, 246, 10.1038/sj.bjc.6604838

Valle, 2014, Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study, J Clin Oncol, 32, 504, 10.1200/JCO.2013.50.7657

Liao, 2013, Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis, Lancet Oncol, 14, 1095, 10.1016/S1470-2045(13)70388-7

Neoptolemos, 2013, Bayesian analysis unravels pancreas cancer adjuvant therapy, Lancet Oncol, 14, 1034, 10.1016/S1470-2045(13)70403-0

Neoptolemos, 2010, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial, JAMA, 304, 1073, 10.1001/jama.2010.1275

Campbell, 2009, Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin, Histopathology, 55, 277, 10.1111/j.1365-2559.2009.03376.x

2010

Peto, 1972, Asymptotically efficient rank invariant test procedures, J R Stat Soc Ser A Stat Soc, 135, 185, 10.2307/2344317

Cox, 1972, Regression models and life tables, J R Stat Soc, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x

White, 2011, Multiple imputation using chained equations: issues and guidance for practice, Stat Med, 30, 377, 10.1002/sim.4067

Akaike, 1974, A new look at the statistical model identification, IEEE Trans Automat Contr, 19, 716, 10.1109/TAC.1974.1100705

Schoenfeld, 1982, Partial residuals for the proportional hazards regression model, Biometrika, 69, 239, 10.1093/biomet/69.1.239

Schemper, 1996, A note on quantifying follow-up in studies of failure time, Contr Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X

Trotti, 2007, TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group, Lancet Oncol, 8, 613, 10.1016/S1470-2045(07)70144-4

Henderson, 2000, Joint modelling of longitudinal measurements and event time data, Biostatistics, 1, 465, 10.1093/biostatistics/1.4.465

Peto, 1977, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, Br J Cancer, 35, 1, 10.1038/bjc.1977.1

Uesaka, 2016, Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01), Lancet, 388, 248, 10.1016/S0140-6736(16)30583-9

Sinn, 2015, CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—a prospective randomized phase III study, J Clin Oncol, 33

Vivaldi, 2016, First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: patients' outcome and analysis of prognostic factors, Int J Cancer, 10.1002/ijc.30125

Reni, 2012, A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen), Cancer Chemother Pharmacol, 69, 115, 10.1007/s00280-011-1680-2

Greenhalf, 2014, Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 Trial, J Natl Cancer Inst, 106, djt347, 10.1093/jnci/djt347

Capello, 2015, Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma, J Natl Cancer Inst, 107, djv132, 10.1093/jnci/djv132